BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

 BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Shots:

  • The P-III head-to-head APSEN trial involves assessing Brukinsa (160 mg, PO, bid) vs ibrutinib (420 mg, PO, qd) in 652 patients with r/r CLL or SLL, until disease progression or unacceptable toxicity
  • The interim analysis of the trial met its 1EP & pre-specified 2EPs i.e superior ORR & lower risk of atrial fibrillation or flutter respectively. PFS showed an early trend favoring Brukinsa
  • BeiGene plans to consult with global regulatory authorities and present the data at an upcoming major medical conference. The ongoing study with pre-specified endpoints of ORR and PFS will be further evaluated at the planned final analysis expected in 2022

Click here to­ read full press release/ article | Ref: Business Wire | Image: Yicai Global

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post